Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Upcoming ...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(379)
•••
Comment by Benedictuson Dec 13, 2022 11:01pm
201 Views
Post# 35170059

RE:RE:RE:RE:RE:RE:RE:Upcoming ...

RE:RE:RE:RE:RE:RE:RE:Upcoming ...

MrMugsy wrote:
woundedknee wrote: About time for Dan to sell some more of his shares. Christmas bills coming up. lol



Hahaha - I don't think it works that way but I could be wrong.

I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong.  I would have done that myself.

Also - I'd be more concerned about unexpected sales like the one by Wallace out of nowhere.  The unknown and unexpected is a little harder to swallow.  Then again, to sell at lows is more preferred than selling at highs - I respect that part of Wallace's sale.

Going forward - don't think we'll see any selling from Dan/John as we head into P2 excitement.  Just my opinion.

Personally - I would have taken some of our cash and used it to buyback shares at this level - or at least threaten to do so.  It would have been the absolute wrong approach with our cash ... but I would have threatened it none-the-less.         : )

 

Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management.  They need every damn penny on hand and then some...and the market knows it.  I'm pleased they're just sticking to their knitting, don't need to dilute near term and moving everything forward. 2023 should be a better year for the longs and within 12 months, give or take, we will have successful acute p2 results. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities